BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829-834. [PMID: 15178498 DOI: 10.1016/j.amjmed.2003.12.040] [Cited by in Crossref: 199] [Cited by in F6Publishing: 176] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
2 Dore GJ, Guan R, Wasim Jafri SM, Sarin SV, Keeffe EB. Management of chronic hepatitis B in challenging patient populations. Liver International 2006;26:38-46. [DOI: 10.1111/j.1478-3231.2006.01375.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
3 Li XK, Zhang MX, Shao FZ, Zhou DQ, Xue JD, Liu TJ, Chi XL, Lu BJ, Wang XB, Li Q, Li J, Mao DW, Yang HS, Yang HZ, Zhao WX, Li Y, Zhang GL, Zhao YM, Zou JD, Liu MY, Zhang KK, Yang XZ, Gan DN, Li Y, Zhang P, Li ZG, Li S, Ye YA. Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial. Chin J Integr Med 2020;26:330-8. [PMID: 31919749 DOI: 10.1007/s11655-020-3250-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ni YH, Chang MH, Hsu HY, Tung YC, Chen HL, Wang KJ, Tsuei DJ, Young NC. Mutations of T-cell epitopes in the hepatitis B virus surface gene in children with chronic infection and hepatocellular carcinoma. Am J Gastroenterol 2008;103:1004-9. [PMID: 18190649 DOI: 10.1111/j.1572-0241.2007.01727.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ko YL, Sun CS, Chung KM, Lin YM, Feng IC, Sheu MJ, Koay LB, Lin CY, Ho CH, Kuo HT. Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion. PLoS One. 2015;10:e0117590. [PMID: 25689069 DOI: 10.1371/journal.pone. 0117590] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Frenette CT, Gish RG. To "be" or not to "be": that is the question. Am J Gastroenterol 2009;104:1948-52. [PMID: 19661938 DOI: 10.1038/ajg.2009.204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
7 Han Q, Li N, Zhu Q, Li Z, Zhang G, Chen J, Lv Y, Wang Y, Liu Z, Hao C. Association of serum soluble human leukocyte antigen-G levels with chronic hepatitis B virus infection. Clin Exp Med 2014;14:35-43. [DOI: 10.1007/s10238-012-0214-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
8 Zhou T, Lai X, Feng M, Tang Y, Zhang L, Wei J. Systematic review and meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion. J Viral Hepat 2018;25:1172-9. [DOI: 10.1111/jvh.12928] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
9 Lee JI, Park HJ, Lee JW, Kim YS, Jeong S, Lee DH, Kim HG, Shin YW, Kwon KS. Pretreatment alanine transaminase level may not be the most important predictor of HBeAg loss in the older patient. Liver International 2009;29:231-6. [DOI: 10.1111/j.1478-3231.2008.01815.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Shi KD, Hwang SG, Choi JH, Hwang IJ, Yoon JH, Kim KI, Kwon CI, Hong SP, Park PW, Rim KS. [Hepatitis B core antigen expression pattern predicts response to lamivudine therapy in patients with chronic hepatitis B]. Korean J Hepatol 2008;14:197-205. [PMID: 18617767 DOI: 10.3350/kjhep.2008.14.2.197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Palumbo E. Lamivudine for Chronic Hepatitis B in Children: A Review. Infectious Diseases in Clinical Practice 2008;16:13-5. [DOI: 10.1097/ipc.obo13e31815aa2dd] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int 2007;1:311-5. [PMID: 19669355 DOI: 10.1007/s12072-007-9002-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
13 Marzio DHD, Hann HW. Then and now: The progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014; 20(2): 401-413 [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
14 Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol. 2009;104:1693-1699. [PMID: 19455130 DOI: 10.1038/ajg.2009.187] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 5.1] [Reference Citation Analysis]
15 Tseng T, Liu C, Yang W, Chen C, Yang H, Su T, Wang C, Kuo SF, Liu C, Chen P, Chen D, Kao J. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters: HBsAg levels predict viral reactivation. J Gastroenterol Hepatol 2014;29:1242-9. [DOI: 10.1111/jgh.12502] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
16 Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol. 2008;2:553-562. [PMID: 19072403 DOI: 10.1586/17474124.2.4.553] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
17 Chen CH, Lee CM, Lu SN, Changchien CS, Eng HL, Huang CM, Wang JH, Hung CH, Hu TH. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J Clin Microbiol. 2005;43:6000-6006. [PMID: 16333089 DOI: 10.1128/jcm.43.12.6000-6006.2005] [Cited by in Crossref: 71] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
18 Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133:1458-1465. [PMID: 17935720 DOI: 10.1053/j.gastro.2007.08.039] [Cited by in Crossref: 119] [Cited by in F6Publishing: 110] [Article Influence: 8.5] [Reference Citation Analysis]
19 Allain JP. Epidemiology of Hepatitis B virus and genotype. J Clin Virol. 2006;36 Suppl 1:S12-S17. [PMID: 16831687 DOI: 10.1016/s1386-6532(06)80003-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Vallet-Pichard A, Mallet V, Costentin CE, Pol S. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther. 2009;7:527-535. [PMID: 19485793 DOI: 10.1586/eri.09.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
21 Sinn DH. [Natural History and Treatment Indications of Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:245-50. [PMID: 31765552 DOI: 10.4166/kjg.2019.74.5.245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Nousbaum JB. [A 23-year-old asymptomatic HBsAg positive woman]. Gastroenterol Clin Biol 2009;33:F56-9. [PMID: 19762187 DOI: 10.1016/j.gcb.2009.07.029] [Reference Citation Analysis]
23 Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29 Suppl 1:100-107. [PMID: 19207972 DOI: 10.1111/j.1478-3231.2008.01941.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 140] [Article Influence: 12.1] [Reference Citation Analysis]
24 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH;  American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1062] [Article Influence: 193.2] [Reference Citation Analysis]
25 Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010;30:512-520. [PMID: 20102511 DOI: 10.1111/j.1478-3231.2009.02198.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
26 Jafri SR, Lok AS. Antiviral Therapy for Chronic Hepatitis B. Clinics in Liver Disease 2010;14:425-38. [DOI: 10.1016/j.cld.2010.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
27 Moucari R, Marcellin P. [HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome]. Gastroenterol Clin Biol. 2010;34 Suppl 2:S119-S125. [PMID: 21095515 DOI: 10.1016/s0399-8320(10)70031-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
28 Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51:435-444. [PMID: 19918971 DOI: 10.1002/hep.23348] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 10.8] [Reference Citation Analysis]
29 Liaw Y, Leung N, Guan R, Lau GK, Merican I, Mccaughan G, Gane E, Kao J, Omata M; for the Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-89. [DOI: 10.1111/j.1478-3231.2005.01134.x] [Cited by in Crossref: 239] [Cited by in F6Publishing: 236] [Article Influence: 14.9] [Reference Citation Analysis]
30 Xie Q, Hu X, Zhang Y, Jiang X, Li X, Li J. Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B. J Med Virol. 2014;86:1828-1837. [PMID: 25145769 DOI: 10.1002/jmv.24000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
31 Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009;51:403-10. [PMID: 19467727 DOI: 10.1016/j.jhep.2009.04.003] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 6.9] [Reference Citation Analysis]
32 Roushan MR, Bijani A, Ramzaninejad S, Roushan MH, Amiri MJ, Baiani M. HBeAg seroconversion in children infected during early childhood with hepatitis B virus. J Clin Virol. 2012;55:30-33. [PMID: 22727680 DOI: 10.1016/j.jcv.2012.05.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
33 Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, McConkey S, Goedert JJ, Kaye S, Rowland-Jones S, Whittle H, Kirk GD. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat. 2010;17:115-122. [PMID: 19874478 DOI: 10.1111/j.1365-2893.2009.01168.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 5.0] [Reference Citation Analysis]
34 Candotti D, Opare-sem O, Rezvan H, Sarkodie F, Allain J. Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine aminotransferase. J Viral Hepat 2006;13:715-24. [DOI: 10.1111/j.1365-2893.2006.00741.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 3.6] [Reference Citation Analysis]
35 Wu JF, Chiu YC, Chang KC, Chen HL, Ni YH, Hsu HY, Chang MH. Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood. Hepatology. 2016;63:74-82. [PMID: 26389515 DOI: 10.1002/hep.28222] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
36 Xing YF, Wei CS, Zhou TR, Huang DP, Zhong WC, Chen B, Jin H, Hu XY, Yang ZY, He Q, Jiang KP, Jiang JM, Hu ZB, Deng X, Yang F, Li FY, Zhao G, Wang LC, Mi YQ, Gong ZJ, Guo P, Wu JH, Shi WQ, Yang HZ, Zhou DQ, Tong GD. Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients. World J Gastroenterol 2020; 26(30): 4501-4522 [PMID: 32874061 DOI: 10.3748/wjg.v26.i30.4501] [Reference Citation Analysis]
37 Wu CH, Hsu TY, Kung FT, ChangChien CC, Tsai CC, Lu SN. Changes in the Prevalence of HBsAg and HBeAg: a Study of 8696 Parturients in a Well Vaccinated Area. Sci Rep 2017;7:1212. [PMID: 28450703 DOI: 10.1038/s41598-017-01234-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Chien R. On-treatment monitoring of chronic hepatitis B virus infection: An Asian-Pacific perspective: On-treatment monitoring of HBV infection. Journal of Gastroenterology and Hepatology 2010;25:852-7. [DOI: 10.1111/j.1440-1746.2010.06271.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
39 Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B: HBsAg revisited. Liver International 2011;31:122-8. [DOI: 10.1111/j.1478-3231.2010.02390.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
40 Arora A, Singh SP, Kumar A, Saraswat VA, Aggarwal R, Bangar M, Bhaumik P, Devarbhavi H, Dhiman RK, Dixit VK, Goel A, Goswami B, Kapoor D, Madan K, Narayan J, Nijhawan S, Pandey G, Rai RR, Sahu MK, Saraf N, Shalimar, Shenoy T, Thomas V, Wadhawan M; INASL Hepatitis B Taskforce. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. J Clin Exp Hepatol 2018;8:58-80. [PMID: 29743798 DOI: 10.1016/j.jceh.2017.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
41 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275-284. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 171] [Cited by in F6Publishing: 164] [Article Influence: 17.1] [Reference Citation Analysis]
42 Lin C, Tseng T, Kao J. What can we learn from hepatitis B virus clinical cohorts? Liver Int 2015;35:91-9. [DOI: 10.1111/liv.12716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
43 Dumas L, Vergani D, Mieli-vergani G. Hepatitis B Virus: Something Old, Something New. Journal of Pediatric Gastroenterology & Nutrition 2007;44:14-7. [DOI: 10.1097/01.mpg.0000252189.20417.84] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
44 Ringelhan M, O'Connor T, Protzer U, Heikenwalder M. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol. 2015;235:355-367. [PMID: 25196558 DOI: 10.1002/path.4434] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 13.0] [Reference Citation Analysis]
45 Andreani T, Serfaty L, Mohand D, Dernaika S, Wendum D, Chazouillères O, Poupon R. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol. 2007;5:636-641. [PMID: 17428739 DOI: 10.1016/j.cgh.2007.01.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.5] [Reference Citation Analysis]
46 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int. 2011;31:676-684. [PMID: 21457439 DOI: 10.1111/j.1478-3231.2011.02490.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
48 Lin C, Kao J. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008;15:137-45. [DOI: 10.1007/s11373-007-9225-8] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 5.8] [Reference Citation Analysis]
49 Fung J, Lai CL, Seto WK, Wong DK, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. J Viral Hepat. 2011;18:738-744. [PMID: 20659306 DOI: 10.1111/j.1365-2893.2010.01355.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
50 Pinarbasi B, Onel D, Cosan F, Akyuz F, Dirlik N, Cakaloglu Y, Badur S, Besisik F, Demir K, Okten A. Prevalence and virological features of occult hepatitis B virus infection in female sex workers who work uncontrolled in Turkey. Liver Int. 2009;29:227-230. [PMID: 18662283 DOI: 10.1111/j.1478-3231.2008.01809.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
51 Li MH, Xie Y, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Hu LP, Hua WH, Song SJ, Zhang SF, Cheng J, Xu DZ. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World J Hepatol 2016; 8(15): 637-643 [PMID: 27239256 DOI: 10.4254/wjh.v8.i15.637] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
52 Peng CY, Chen CB, Lai HC, Su WP, Chuang PH, Wu HD, Jeng LB. Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. Hepatol Int 2010;5:586-96. [PMID: 21442057 DOI: 10.1007/s12072-010-9227-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
53 Lu H, Geng da Y, Shen F, Zhang JY, Lu B, Ma LX. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study. Virol J 2011;8:444. [PMID: 21936898 DOI: 10.1186/1743-422X-8-444] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
54 Ferns RB, Naoumov NV, Gilson RJ, Tedder RS. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss. Journal of Clinical Virology 2007;39:199-204. [DOI: 10.1016/j.jcv.2007.04.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
55 Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, Morsica G, Moriondo M, Gatta A. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43:556-562. [PMID: 16496323 DOI: 10.1002/hep.21077] [Cited by in Crossref: 160] [Cited by in F6Publishing: 132] [Article Influence: 10.7] [Reference Citation Analysis]
56 Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology. 2007;133:1466-1474. [PMID: 17915220 DOI: 10.1053/j.gastro.2007.09.002] [Cited by in Crossref: 167] [Cited by in F6Publishing: 167] [Article Influence: 11.9] [Reference Citation Analysis]
57 Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. The Lancet Infectious Diseases 2007;7:402-9. [DOI: 10.1016/s1473-3099(07)70135-4] [Cited by in Crossref: 201] [Cited by in F6Publishing: 89] [Article Influence: 14.4] [Reference Citation Analysis]
58 Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727-2734. [PMID: 20238245 DOI: 10.1007/s10620-010-1179-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
59 Tseng T, Liu C, Su T, Wang C, Chen C, Chen P, Chen D, Kao J. Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. Gastroenterology 2011;141:517-525.e2. [DOI: 10.1053/j.gastro.2011.04.046] [Cited by in Crossref: 138] [Cited by in F6Publishing: 142] [Article Influence: 13.8] [Reference Citation Analysis]
60 Chen C, Lee C, Lu S, Changchien C, Wang J, Wang J, Hung C, Hu T. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. Journal of Hepatology 2006;44:76-82. [DOI: 10.1016/j.jhep.2005.08.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
61 Cornberg M, Lok AS, Terrault NA, Zoulim F, Berg T, Brunetto MR, Buchholz S, Buti M, Chan HL, Chang K, Dandri M, Dusheiko G, Feld JJ, Ferrari C, Ghany M, Janssen HL, Kennedy P, Lampertico P, Liang J, Locarnini S, Maini MK, Mishra P, Papatheodoridis G, Petersen J, Schlottmann S, Wang S, Wedemeyer H. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology 2020;72:539-57. [DOI: 10.1016/j.jhep.2019.11.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 60.0] [Reference Citation Analysis]
62 Yang SC, Lu SN, Lee CM, Hu TH, Wang JH, Hung CH, Changchien CS, Chen CH. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion. Hepatol Int. 2013;7:489-499. [PMID: 26201781 DOI: 10.1007/s12072-012-9382-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
63 Chen CH, Lu SN, Lee CM, Hung CH, Wang JH, Hu TH. Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion. Hepatol Int 2014;8:365-74. [PMID: 26202639 DOI: 10.1007/s12072-014-9542-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
64 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Rouet F, Chaix M, Inwoley A, Anaky M, Fassinou P, Kpozehouen A, Rouzioux C, Blanche S, Msellati P; Programme Enfant Yopougon (Agence Nationale de Recherches sur le SIDA et les Hepatites Virales B et C 1244/1278). Frequent Occurrence of Chronic Hepatitis B Virus Infection among West African HIV Type-1--Infected Children. Clinical Infectious Diseases 2008;46:361-6. [DOI: 10.1086/525531] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
66 Huang YW, Liao YT, Chen W, Chen CL, Hu JT, Liu CJ, Lai MY, Chen PJ, Chen DS, Yang SS, Kao JH. Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Genes Immun. 2010;11:87-93. [PMID: 19693091 DOI: 10.1038/gene.2009.65] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
67 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 660] [Article Influence: 48.9] [Reference Citation Analysis]
68 Kumar M, Chauhan R, Gupta N, Hissar S, Sakhuja P, Sarin SK. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology. 2009;136:1272-1280. [PMID: 19208347 DOI: 10.1053/j.gastro.2009.01.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
69 Alexopoulou A, Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol 2014; 20(24): 7644-7652 [PMID: 24976702 DOI: 10.3748/wjg.v20.i24.7644] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
70 Chu C, Liaw Y. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007;14:147-52. [DOI: 10.1111/j.1365-2893.2006.00810.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 107] [Article Influence: 7.9] [Reference Citation Analysis]
71 Murata K, Sugimoto K, Shiraki K, Nakano T. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection. World J Gastroenterol 2005; 11(43): 6848-6852 [PMID: 16425395 DOI: 10.3748/wjg.v11.i43.6848] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
72 Combet C, Bhardwaj N, Hedskog C, Podlaha O, Gaggar A, Murray KF, Mo H, Svarovskaia E, Zoulim F. Hepatitis B virus genome diversity in adolescents: Tenofovir disoproxil fumarate treatment effect and HBeAg serocon version. J Viral Hepat 2021;28:1160-8. [PMID: 34002910 DOI: 10.1111/jvh.13547] [Reference Citation Analysis]
73 Liu LZ, Sun J, Hou J, Chan HLY. Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2018;12:1153-66. [DOI: 10.1080/17474124.2018.1530986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
74 Wu JF, Chang MH. Natural history of chronic hepatitis B virus infection from infancy to adult life - the mechanism of inflammation triggering and long-term impacts. J Biomed Sci. 2015;22:92. [PMID: 26487087 DOI: 10.1186/s12929-015-0199-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
75 Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009: Management of HBV: Consensus of JSH 2009. Hepatology Research 2011;41:1-21. [DOI: 10.1111/j.1872-034x.2010.00739.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Chen Y, Liaw Y. Pharmacotherapeutic options for hepatitis B. Expert Opinion on Pharmacotherapy 2016;17:355-67. [DOI: 10.1517/14656566.2016.1118056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
77 Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173-S181. [PMID: 16447285 DOI: 10.1002/hep.20956] [Cited by in Crossref: 333] [Cited by in F6Publishing: 295] [Article Influence: 22.2] [Reference Citation Analysis]
78 Tseng T, Liu C, Su T, Yang H, Wang C, Chen C, Kuo SF, Liu C, Chen P, Chen D, Kao J. Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. Journal of Infectious Diseases 2012;206:1521-31. [DOI: 10.1093/infdis/jis569] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
79 Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008;48:335-52. [DOI: 10.1016/j.jhep.2007.11.011] [Cited by in Crossref: 791] [Cited by in F6Publishing: 746] [Article Influence: 60.8] [Reference Citation Analysis]
80 Sarin SK, Kumar M. Should chronic HBV infected patients with normal ALT treated: debate. Hepatol Int 2008;2:179-84. [PMID: 19669302 DOI: 10.1007/s12072-008-9065-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
81 Hu CC, Jeng WJ, Chen YC, Fang JH, Huang CH, Teng W, Hsieh YC, Lin YC, Chien RN, Sheen IS, Lin CY. Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/Tim-3 interaction. Sci Rep 2017;7:15280. [PMID: 29127350 DOI: 10.1038/s41598-017-15527-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
82 Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009;3:5-15. [PMID: 19763714 DOI: 10.1007/s12072-009-9149-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
83 Choe HJ, Choe BH. What physicians should know about the management of chronic hepatitis B in children: East side story. World J Gastroenterol 2014; 20(13): 3582-3589 [PMID: 24707141 DOI: 10.3748/wjg.v20.i13.3582] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
84 Chen CH, Lee CM, Wang JH, Hu TH, Hung CH, Changchien CS, Lu SN. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. Hepatol Int 2013;7:477-88. [PMID: 26201780 DOI: 10.1007/s12072-012-9381-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
85 Dai C, Chuang W, Ho C, Yu M. Hepatitis C viremia and serum lipid levels: A clue from an epidemiology study. Journal of Hepatology 2009;50:422-3. [DOI: 10.1016/j.jhep.2008.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Wong GL. Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol 2014;20:228-36. [PMID: 25320725 DOI: 10.3350/cmh.2014.20.3.228] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
87 Cornberg M, Lok AS, Terrault NA, Zoulim F;  2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology. 2019;. [PMID: 31713892 DOI: 10.1002/hep.31030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
88 Sayed SK, Kobeisy MA. The relationship between core promoter mutation of hepatitis B virus, viral load and hepatitis B e antigen status in chronic hepatitis B patients. Cell Immunol. 2012;276:35-41. [PMID: 22551558 DOI: 10.1016/j.cellimm.2012.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
89 Angounda BM, Ngouloubi GH, Dzia AB, Boumba LMA, Baha W, Moukassa D, Ahombo G, Ennaji MM, Ibara JR. Molecular characterization of hepatitis B virus among chronic hepatitis B patients from Pointe Noire, Republic of Congo. Infect Agent Cancer 2016;11:51. [PMID: 27651827 DOI: 10.1186/s13027-016-0088-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
90 Park JY, Park YN, Kim DY, Paik YH, Lee KS, Moon BS, Han KH, Chon CY, Ahn SH. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat. 2008;15:615-621. [PMID: 18573162 DOI: 10.1111/j.1365-2893.2008.00989.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
91 Fung J, Seto W, Wong DK, Lai C, Yuen M. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study. Liver Int 2015;35:854-9. [DOI: 10.1111/liv.12596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
92 Ye YA, Li XK, Zhou DQ, Chi XL, Li Q, Wang L, Lu BJ, Mao DW, Wu QK, Wang XB, Zhang MX, Xue JD, Li Y, Lu W, Guo JC, Jiang F, Zhang XW, Du HB, Yang XZ, Guo H, Gan DN, Li ZG. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial. Chin J Integr Med 2018;24:653-60. [PMID: 30209792 DOI: 10.1007/s11655-018-3011-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
93 Liu Y, Veeraraghavan V, Pinkerton M, Fu J, Douglas MW, George J, Tu T. Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Front Microbiol 2021;12:665201. [PMID: 34194408 DOI: 10.3389/fmicb.2021.665201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Xiong F, Bao X, Gu N, Guo J, Wang J, Ma Y, Yu L, Gao Y, Tan B, Lu J. The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk. Infect Genet Evol 2020;78:104101. [PMID: 31689542 DOI: 10.1016/j.meegid.2019.104101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus AD, Pas SD, Janssen HL, Boonstra A. Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells. Hepatology. 2015;62:87-100. [PMID: 25808668 DOI: 10.1002/hep.27805] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 13.2] [Reference Citation Analysis]
96 Colombatto P, Barbera C, Bortolotti F, Maina AM, Moriconi F, Cavallone D, Calvo P, Oliveri F, Bonino F, Brunetto MR. HBV pre-core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood. J Med Virol 2018;90:1232-9. [PMID: 29488227 DOI: 10.1002/jmv.25068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
97 Wang GQ, Ding YP, Dong YH. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat. 2013;20 Suppl 1:9-17. [PMID: 23458520 DOI: 10.1111/jvh.12059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
98 Hui C, Leung N, Yuen S, Zhang H, Leung K, Lu L, Cheung SKF, Wong W, Lau GK; Hong Kong Liver Fibrosis Study Group. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007;46:395-401. [DOI: 10.1002/hep.21724] [Cited by in Crossref: 142] [Cited by in F6Publishing: 146] [Article Influence: 10.1] [Reference Citation Analysis]
99 Yang H, Kao J. Revisiting the Natural History of Chronic HBV Infection. Curr Hepatology Rep 2016;15:141-9. [DOI: 10.1007/s11901-016-0304-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
100 Chien R. A great deal of learning from the natural course of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2007;22:962-4. [DOI: 10.1111/j.1440-1746.2007.05063.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 De Clercq E. Current treatment of hepatitis B virus infections: Current treatment of HBV Infections. Rev Med Virol 2015;25:354-65. [DOI: 10.1002/rmv.1849] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
102 Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20:426-439, table of contents. [PMID: 17630333 DOI: 10.1128/cmr.00009-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
103 Mojsiejczuk LN, Torres C, Sevic I, Badano I, Malan R, Flichman DM, Liotta DJ, Campos RH. Molecular epidemiology of hepatitis B virus in Misiones, Argentina. Infect Genet Evol 2016;44:34-42. [PMID: 27321439 DOI: 10.1016/j.meegid.2016.06.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
104 Heidrich B, C. Serrano B, Idilman R, Kabaçam G, Bremer B, Raupach R, Önder FO, Deterding K, Zacher BJ, Taranta A, Bozkaya H, Zachou K, Tillmann HL, Bozdayi AM, Manns MP, Yurdaydın C, Wedemeyer H. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int 2012;32:1415-25. [DOI: 10.1111/j.1478-3231.2012.02831.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
105 Skupsky J, Hu K. Current hepatitis B treatment guidelines and future research directions. Front Med 2014;8:145-57. [DOI: 10.1007/s11684-014-0335-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
106 González López Ledesma MM, Mojsiejczuk LN, Rodrigo B, Sevic I, Mammana L, Galdame O, Gadano A, Fainboim H, Campos R, Flichman D. Hepatitis B virus genotype distribution and genotype-specific BCP/preCore substitutions in acute and chronic infections in Argentina. PLoS One 2015;10:e0121436. [PMID: 25822666 DOI: 10.1371/journal.pone.0121436] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
107 Rajoriya N, Combet C, Zoulim F, Janssen HLA. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67:1281-1297. [PMID: 28736138 DOI: 10.1016/j.jhep.2017.07.011] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 16.8] [Reference Citation Analysis]
108 Kramvis A. The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics. Rev Med Virol 2016;26:285-303. [PMID: 27139263 DOI: 10.1002/rmv.1885] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
109 Morrison BJ, Labo N, Miley WJ, Whitby D. Serodiagnosis for tumor viruses. Semin Oncol 2015;42:191-206. [PMID: 25843726 DOI: 10.1053/j.seminoncol.2014.12.024] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
110 Chu CM, Chen YC, Tai DI, Liaw YF. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol. 2010;8:535-540. [PMID: 20304099 DOI: 10.1016/j.cgh.2010.03.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
111 Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes (Lond) 2007;31:871-5. [PMID: 17047638 DOI: 10.1038/sj.ijo.0803479] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
112 Ko YL, Sun CS, Chung KM, Lin YM, Feng IC, Sheu MJ, Koay LB, Lin CY, Ho CH, Kuo HT. Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion. PLoS One. 2015;10:e0117590. [PMID: 25689069 DOI: 10.1371/journal.pone.0117590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
113 Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis: TREATMENT OF IMMUNE TOLERANT HBV. Alimentary Pharmacology & Therapeutics 2007;26:383-91. [DOI: 10.1111/j.1365-2036.2007.03382.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
114 Nakazawa T, Shibuya A, Takeuchi A, Shibata Y, Hidaka H, Okuwaki Y, Takada J, Tanaka Y, Watanabe M, Minamino T. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels. J Viral Hepat. 2011;18:e191-e199. [PMID: 21692932 DOI: 10.1111/j.1365-2893.2010.01427.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
115 Liaw Y, Chu C. Hepatitis B virus infection. The Lancet 2009;373:582-92. [DOI: 10.1016/s0140-6736(09)60207-5] [Cited by in Crossref: 833] [Cited by in F6Publishing: 365] [Article Influence: 69.4] [Reference Citation Analysis]
116 Osman HA, Ghweil AA, Sabry AM, Mahdy RE, Khodeary A. Management Of Patients With Hepatitis B Virus Reactivation Post-DAA Treatment Of Chronic Hepatitis C Virus Infection In HCV-HBV Coinfected Patients With Pretreatment HBeAg Seroconversion And Early Degree Of Hepatic Fibrosis. Infect Drug Resist 2019;12:3067-73. [PMID: 31632097 DOI: 10.2147/IDR.S215974] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
117 Sali S, Alavian SM, Foster GR, Keyvani H, Mehrnoosh L, Mohammadi N. Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. Hepat Mon 2013;13:e8743. [PMID: 24066002 DOI: 10.5812/hepatmon.8743] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
118 Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B. J Med Virol 2007;79:1286-92. [DOI: 10.1002/jmv.20928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
119 Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol. 2013;48:13-21. [PMID: 23090000 DOI: 10.1007/s00535-012-0668-y] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
120 Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol. 2011;55:183-191. [PMID: 21238520 DOI: 10.1016/j.jhep.2010.12.030] [Cited by in Crossref: 107] [Cited by in F6Publishing: 100] [Article Influence: 10.7] [Reference Citation Analysis]
121 Choe B. The management and treatment of chronic hepatitis B in Korean children. Korean J Pediatr 2007;50:823. [DOI: 10.3345/kjp.2007.50.9.823] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
122 Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int. 2007;1:415-430. [PMID: 19669337 DOI: 10.1007/s12072-007-9033-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 74] [Article Influence: 4.8] [Reference Citation Analysis]
123 Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008;23:1182-1192. [PMID: 18637060 DOI: 10.1111/j.1440-1746.2008.05400.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
124 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 23.0] [Reference Citation Analysis]
125 Chiang CH, Lai JS, Sheu JC, Yen LL, Liu CJ, Huang KC. The risky body mass index ranges for significant hepatitis B viral load: A campus-based study. Obes Res Clin Pract. 2012;6:e1-e90. [PMID: 24331171 DOI: 10.1016/j.orcp.2011.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
126 Lisker-melman M, Sayuk GS. Defining Optimal Therapeutic Outcomes in Chronic Hepatitis. Archives of Medical Research 2007;38:652-60. [DOI: 10.1016/j.arcmed.2006.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
127 Yuen M. Revisiting the natural history of chronic hepatitis B: Impact of new concepts on clinical management. J Gastroenterol Hepatol 2007;22:973-6. [DOI: 10.1111/j.1440-1746.2007.04938.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
128 Tseng T, Liu C, Chen C, Wang C, Su T, Kuo SF, Chen P, Chen D, Kao J. Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. The Journal of Infectious Diseases 2012;205:54-63. [DOI: 10.1093/infdis/jir687] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
129 Liaw Y. Role of antiviral therapy of HBV in the prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:S128-30. [DOI: 10.1111/j.1440-1746.2004.03662.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
130 Lee HW, Ahn SH, Chan HL. Hepatitis B Core-Related Antigen: From Virology to Clinical Application. Semin Liver Dis 2021;41:182-90. [PMID: 33957693 DOI: 10.1055/s-0041-1723088] [Reference Citation Analysis]
131 Hadziyannis SJ, Vassilopoulos D, Hadziyannis E. The natural course of chronic hepatitis B virus infection and its management. Adv Pharmacol. 2013;67:247-291. [PMID: 23886003 DOI: 10.1016/B978-0-12-405880-4.00007-X] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
132 Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, Njie R, Njai H, Lemoine M, Hallett TB, Thursz M. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. Lancet Glob Health 2016;4:e568-78. [PMID: 27443782 DOI: 10.1016/S2214-109X(16)30101-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 23] [Article Influence: 20.3] [Reference Citation Analysis]
133 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
134 Lin B, Ha NB, Liu A, Trinh HN, Nguyen HA, Nguyen KK, Ahmed A, Keeffe EB, Garcia RT, Garcia G. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013;28:855-860. [PMID: 23278507 DOI: 10.1111/jgh.12108] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
135 Zaghloul H, El-Sherbiny W. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest. 2010;39:284-291. [PMID: 20380524 DOI: 10.3109/08820131003605820] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
136 Wu JF, Chang KC, Ni YH, Hsu HY, Chang MH. Impacts of the Percentage of Basal Core Promoter Mutation on the Progression of Liver Fibrosis After Hepatitis B e Antigen Seroconversion. J Infect Dis 2021;223:1381-9. [PMID: 32860707 DOI: 10.1093/infdis/jiaa545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Alavian SM, Imanieh MH, Imanieh MH. Predictive Factors in the Incidence of Cirrhosis in Chronic Hepatitis B Virus Infections. Hepat Mon. 2016;16:e34790. [PMID: 27330536 DOI: 10.5812/hepatmon.34790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
138 Liaw Y, Sollano JD. Factors influencing liver disease progression in chronic hepatitis B. Liver International 2006;26:23-9. [DOI: 10.1111/j.1478-3231.2006.01372.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
139 Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ;  Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138:1747-1754. [PMID: 20114048 DOI: 10.1053/j.gastro.2010.01.042] [Cited by in Crossref: 213] [Cited by in F6Publishing: 190] [Article Influence: 19.4] [Reference Citation Analysis]
140 Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007;45:1187-92. [PMID: 17465003 DOI: 10.1002/hep.21612] [Cited by in Crossref: 237] [Cited by in F6Publishing: 216] [Article Influence: 16.9] [Reference Citation Analysis]
141 Peng C, Lai H, Li Y, Su W, Chuang P, Kao J. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2012;35:458-68. [DOI: 10.1111/j.1365-2036.2011.04973.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
142 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 120] [Article Influence: 12.1] [Reference Citation Analysis]
143 Ha NB, Trinh HN, Rosenblatt L, Nghiem D, Nguyen MH. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice. Journal of Clinical Gastroenterology 2016;50:169-74. [DOI: 10.1097/mcg.0000000000000345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
144 Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA 2018;319:1802. [DOI: 10.1001/jama.2018.3795] [Cited by in Crossref: 194] [Cited by in F6Publishing: 187] [Article Influence: 64.7] [Reference Citation Analysis]
145 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
146 Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005;43:411-417. [PMID: 16006001 DOI: 10.1016/j.jhep.2005.03.018] [Cited by in Crossref: 123] [Cited by in F6Publishing: 122] [Article Influence: 7.7] [Reference Citation Analysis]
147 Chu CM, Liaw YF. Letter to the Editor: Age at Hepatitis B e Antigen Seroconversion and Other Factors for Outcomes of Chronic Hepatitis B. Hepatology 2019;69:2711. [PMID: 30014494 DOI: 10.1002/hep.30179] [Reference Citation Analysis]
148 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 658] [Article Influence: 77.2] [Reference Citation Analysis]
149 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 27.3] [Reference Citation Analysis]
150 Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. Sci Rep 2019;9:2508. [PMID: 30792468 DOI: 10.1038/s41598-019-39043-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
151 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.6] [Reference Citation Analysis]
152 Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology. 2009;49:1859-1867. [PMID: 19378345 DOI: 10.1002/hep.22878] [Cited by in Crossref: 111] [Cited by in F6Publishing: 100] [Article Influence: 9.3] [Reference Citation Analysis]
153 Koc ÖM, Robaeys G, Topal H, Bielen R, Busschots D, Fevery J, Koek GH, Nevens F. Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: A long-term observational cohort study. J Med Virol 2020. [PMID: 32343427 DOI: 10.1002/jmv.25950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016;36:1239-1251. [PMID: 27062182 DOI: 10.1111/liv.13142] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 13.0] [Reference Citation Analysis]
155 Kuo L, Lee C, Hung C, Wang J, Hu T, Lu S, Changchien C, Chen C. High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years. Dig Dis Sci 2014;59:2580-7. [DOI: 10.1007/s10620-014-3194-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
156 Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009;49:S129-37. [PMID: 19399799 DOI: 10.1002/hep.22931] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
157 Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HL, Belle SH, Hoofnagle JH; Hepatitis B Research Network (HBRN). Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat. 2017;24:320-329. [PMID: 27917600 DOI: 10.1111/jvh.12643] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
158 Huang YW, Hu CY, Chen CL, Liao YT, Liu CJ, Lai MY, Chen PJ, Yang SS, Hu JT, Chen DS. Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. J Med Virol. 2009;81:588-593. [PMID: 19235869 DOI: 10.1002/jmv.21448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
159 Hadziyannis SJ. Unrevealing the natural course of the so-called “inactive HBsAg or HBV carrier state”. Hepatol Int. 2007;1:281-284. [PMID: 19669350 DOI: 10.1007/s12072-007-9004-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
160 Stasi C, Silvestri C, Berni R, Brunetto MR, Zignego AL, Orsini C, Milani S, Ricciardi L, De Luca A, Blanc P, Nencioni C, Aquilini D, Bartoloni A, Bresci G, Marchi S, Filipponi F, Colombatto P, Forte P, Galli A, Luchi S, Chigiotti S, Nerli A, Corti G, Sacco R, Carrai P, Ricchiuti A, Giusti M, Almi P, Cozzi A, Carloppi S, Laffi G, Voller F, Cipriani F. Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-world large-scale cohort study. World J Hepatol 2018; 10(5): 409-416 [PMID: 29844854 DOI: 10.4254/wjh.v10.i5.409] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
161 Nicastro E, Mangili B, Giacomet V, Benincaso AR, Di Giorgio A, Sansotta N, Callegaro A, D’antiga L. Longitudinal Immune Phenotype Assessment and Serological Outcome in Foreign-born Children With Chronic Hepatitis B. Journal of Pediatric Gastroenterology & Nutrition 2020;71:381-7. [DOI: 10.1097/mpg.0000000000002804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
162 Chen CH, Lee CM, Hung CH, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study. Liver Int. 2007;27:806-815. [PMID: 17617124 DOI: 10.1111/j.1478-3231.2007.01505.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
163 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1008] [Article Influence: 179.3] [Reference Citation Analysis]
164 Yu W, Wang Y, Shen C, Ji R, Zhang L, Zhao X, Su M, Zhang Y, He W, Cao J, Hao Y, Chen S, Zhao C. Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting. Braz J Infect Dis 2017;21:213-8. [PMID: 28351603 DOI: 10.1016/j.bjid.2017.03.001] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021; 27(20): 2474-2494 [PMID: 34092970 DOI: 10.3748/wjg.v27.i20.2474] [Reference Citation Analysis]
166 Han K, Kim DY. Chronic HBV infection with persistently normal ALT b. not to treat. Hepatol Int 2008;2:185-9. [DOI: 10.1007/s12072-008-9068-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
167 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 32.0] [Reference Citation Analysis]
168 Chu C, Lin D, Liaw Y. Clinical and Virological Characteristics Post HBsAg Seroclearance in Hepatitis B Virus Carriers With Hepatic Steatosis Versus Those Without. Dig Dis Sci 2013;58:275-81. [DOI: 10.1007/s10620-012-2343-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
169 Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol. 2020;. [PMID: 32434068 DOI: 10.1016/j.cgh.2020.04.091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
170 Yao CC, Lee CM, Hung CH, Wang JH, Hu TH, Lu SN, Changchien CS, Hsu MC, Chen CH. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. J Gastroenterol Hepatol 2015;30:918-24. [PMID: 25532588 DOI: 10.1111/jgh.12874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
171 Villa E, Fattovich G, Mauro A, Pasino M. Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis. Digestive and Liver Disease 2011;43:S8-S14. [DOI: 10.1016/s1590-8658(10)60686-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
172 Croagh CM, Lubel JS. Natural history of chronic hepatitis B: Phases in a complex relationship. World J Gastroenterol 2014; 20(30): 10395-10404 [PMID: 25132755 DOI: 10.3748/wjg.v20.i30.10395] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
173 Chen YC, Huang SF, Chu CM, Liaw YF. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. J Viral Hepat. 2012;19:138-146. [PMID: 22239503 DOI: 10.1111/j.1365-2893.2011.01450.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
174 Wong GL. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol. 2018;24:108-113. [PMID: 29353469 DOI: 10.3350/cmh.2017.0068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
175 Harkisoen S, Arends JE, van Erpecum KJ, van den Hoek A, Hoepelman AI. Hepatitis B viral load and risk of HBV-related liver disease: from East to West? Annals of Hepatology 2012;11:164-71. [DOI: 10.1016/s1665-2681(19)31020-8] [Cited by in Crossref: 18] [Article Influence: 2.0] [Reference Citation Analysis]
176 Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology. 2012;55:68-76. [PMID: 21858846 DOI: 10.1002/hep.24615] [Cited by in Crossref: 96] [Cited by in F6Publishing: 94] [Article Influence: 10.7] [Reference Citation Analysis]